FDA's Lillian Yin
This article was originally published in The Gray Sheet
Director of the division of reproductive, abdominal, ear nose & throat and radiological devices in FDA's Office of Device Evaluation moves to the Center for Biologics Evaluation and Research in order to work on CBER's action plan for the regulation of devices ("The Gray Sheet" Dec. 7, p. 22). DRAERD Chief Medical Officer Dan Schultz is replacing Yin on an acting basis. Also leaving CDRH to join CBER is Mary Beth Jacobs, director of the division of life sciences within the Office of Science and Technology
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.